GI CONNECT has summarised the highlights from the ASCO GI 2020 meeting for you. Dr Samuel Klempner (USA) provides the highlights on upper GI.
GI CONNECT has summarised the highlights from the ASCO GI 2020 meeting for you. Dr Samuel Klempner (USA) provides the highlights on upper GI.
Dr Samuel J. Klempner is a GI medical oncologist with research and clinical focus on esophagogastric cancers and cancer genomics. Dr Klempner completed his residency in internal medicine at Brigham and Women’s Hospital/Harvard Medical School, followed by a combined hematology-oncology fellowship at Beth Israel Deaconess Medical Center/Harvard Medical School. While at Harvard, Dr Klempner studied the mechanisms of resistance to targeted therapies in tumor cells in the lab of Dr Lewis Cantley, PhD. Dr Klempner is board certified in medical oncology, hematology, and internal medicine. Prior to joining The Angeles Clinic and Research Institute Dr Klempner served as an Assistant Clinical Professor in the division of Hematology-Oncology at the University of California Irvine. Dr Klempner’s research interests include the intersection of genomics and immunotherapies, oncogene-driven tumors, acquired resistance, and experimental therapeutics. Dr Klempner is involved in professional societies including the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), and the European Society for Medical Oncology (ESMO).
Astellas, AstraZeneca, BMS, Coherus, Daiichi-Sankyo, Eli Lilly, Merck, Novartis, Nuvalent Therapuetics and Sanofi.
Recommendations for best practice
Paper published in Journal of Gastrointestinal Cancer
Get your free professional profile photos taken with us at Booth 507
Maximising outcomes for patients with advanced neuroendocrine tumours
Clinical application of liquid biopsy, and how it applies to NSCLC, breast and colorectal cancer
Maximising outcomes for patients with advanced RCC